Appointed
Dr. Gil Aharon
Director
NRXS ·
Neuraxis, INC
the Board appointed Dr. Aharon to the Board, effective January 1, 2025.
Ready 8-Ks
35
Latest filing
August 19, 2026, 5:00 PM ET
Top materiality
0.80
Event mix
other_material ×17 · earnings ×6 · leadership ×4
Sentiment
7 pos · 7 neg · 21 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for NRXS
Highest-materiality recent filing
NeurAxis reports FY2023 net loss $14.6M; restates Q3 2023 due to $3.7M accounting error
- FY2023 revenue $2.5M down 8.4% YoY; net loss widened to $14.6M from $4.8M in 2022.
- Restating Q3 2023 financials: $3.7M understatement of net loss and APIC due to warrant liability misclassification.
-
Neuraxis completes stock option exchange; grants RSUs to execs and directors
Stock Option Exchange effective July 24, 2026: 1,319,394 options cancelled for equivalent RSUs on one-for-one basis.
-
Neuraxis declares Q2 2026 stock dividend on Series B Preferred, payable in common shares
Board authorized Q2 2026 stock dividend on Series B Preferred, payable in common stock.
-
Six director nominees elected: Brian Carrico, Dr. Christopher R Brown, Bradley Mitch Watkins, Beth Keyser, Kristen Ferge, Dr. Gilad Aharon; each received 96-99% of votes.
-
Neuraxis ups ATM offering to $11.5M after selling 1.125M shares under prior $6.27M program
On Apr 21, 2026, Neuraxis filed a prospectus supplement increasing the ATM offering cap to $11,500,000 from $6,270,000.
-
Neuraxis reports preliminary Q1 2026 net sales of $1.6M, up 77% YoY; operating loss of $1.7M
Cash and cash equivalents ~$7.1M as of March 31, 2026.
-
Neuraxis gets FDA 510(k) clearance for PENFS to treat functional dyspepsia in ages 8+
FDA cleared Neuraxis' PENFS for functional abdominal pain associated with functional dyspepsia and nausea in patients 8 years and older.
-
Neuraxis reports preliminary Q3 net sales $0.8M, operating loss $2.1M
Preliminary unaudited cash and equivalents of $4.4M as of September 30, 2025.
-
Neuraxis enters $3.3M ATM offering agreement with Craig-Hallum
ATM offering of up to $3.3M of common stock at prevailing market prices.
-
Neuraxis ends Masimo partnership on NSS-2 Bridge; pays $200K, forfeits future royalties
Terminated License and Collaboration Agreement with Masimo Corp., effective July 1, 2025.
-
Neuraxis stockholders approve Series B conversion stock issuance; elect directors
Votes to approve issuance of 20%+ of outstanding common stock upon conversion of Series B Preferred Stock passed with 4.1M for, 129K against, 1.1M broker non-votes.
-
Neuraxis posts investor presentation to website; no specific financial details disclosed in filing
Investor presentation covering strategy, performance, and objectives posted to ir.neuraxis.com on May 23, 2025.
-
Neuraxis announces $5.0M registered direct offering of 1.54M shares at $3.25/share
Offering of 1,538,461 shares at $3.25/share; gross proceeds ~$5.0M before fees.
-
Neuraxis settles litigation for $750k payable starting Jan 2026; raises ~$1M from warrant exercises
Settles two lawsuits (Physicians' Litigation and Medical Practice Entities' Litigation) for $750,000 total, payable in 12 equal monthly installments beginning January 2026.
-
NeurAxis preliminary Q4 revenue up 50% YoY to ~$800K; cash $3.7M
Preliminary Q4 2024 revenue ~$800K (+50% YoY); FY2024 revenue ~$2.7M (+11% YoY).
-
Neuraxis appoints Dr. Gil Aharon to board effective Jan 1, 2025
Dr. Gil Aharon appointed to Neuraxis board effective Jan 1, 2025, as designee of investors in recent $5M Series B financing.
-
Increased authorized Series B Preferred shares from 4,000,000 to 5,000,000.
-
Neuraxis raises ~$5M through Series B Convertible Preferred Stock to three investors
Sold 2,100,840 shares of Series B Preferred Stock at $2.38 stated value for aggregate $5M, closed Nov 13, 2024.
-
NeurAxis Q3 revenue up 40% to $667K; operating loss narrows 45%; secures $5M investment
Revenue $667K, +40% YoY; unit sales +50%.
-
Neuraxis cuts Flagstaff investment to $1.8M, raises $145k from new Series B preferred sale
Fourth Amendment reduces Flagstaff SPA total from $5M to $1.8M; $800k received, $1M due by Dec 31, 2024.
-
Neuraxis converts $4.94M of convertible notes into 2.07M Series B Preferred shares
$4,935,001.90 of Preferred Stock Notes automatically converted into 2,073,524 Series B Preferred shares at $2.38/share.
-
Neuraxis shareholders approve expanded equity plan and blank check preferred
All five director nominees elected with 85%–99.99% votes for; quorum of 65.61% achieved.
-
Revenue $611.5K, down 5.3% YoY; gross margin 88.0% vs 89.5%.
-
Three non-employee directors (Ferge, Keyser, Watkins) granted fully vested shares for services through March 31, 2024.
-
Neuraxis raises $3M via convertible notes at 8.5% interest; warrants amended
Issued ~$3M aggregate principal convertible notes to three institutional investors; 8.5% annual interest payable quarterly.
-
Neuraxis COO Dan Clarence terminated; severance through Oct 2024
COO Dan Clarence employment terminated effective April 10, 2024.
-
NeurAxis reports FY2023 net loss $14.6M; restates Q3 2023 due to $3.7M accounting error
FY2023 revenue $2.5M down 8.4% YoY; net loss widened to $14.6M from $4.8M in 2022.
-
Neuraxis increases Flagstaff financing to $5M, replaces preferred with convertible note
Amendment raises Flagstaff investment from $3M to $5M via convertible promissory note.
-
NeurAxis appoints Kristin Ferge to Board as Audit Committee Chair
Kristin Ferge, 50, appointed to Board effective March 7, 2024, until next annual meeting.
-
Neuraxis raises $457k via convertible notes; amends Flagstaff $3M SPA
Entered SPAs with two accredited investors on Feb 9 & 14 for $457k aggregate; notes bear 8.5% interest, convertible to Series B Preferred at $2.38/share.
-
NeurAxis appoints Timothy Henrichs as CFO; John Seale resigns
Timothy Henrichs appointed CFO effective Feb 5, 2024, replacing John Seale who resigned Jan 30.
-
Neuraxis lowers warrant exercise price to $2.38; SPA not yet closed
Exercise price of all warrants reduced from $5.25 to $2.38 per share due to SPA with Flagstaff International.
-
Neuraxis secures $3M financing via Series B preferred stock at $2.38/share
Aggregate purchase price $3,000,000; paid in 15 monthly installments of $200,000 each.
-
Neuraxis Q2 2023 revenue down 5% to $646K; net loss widens to $2.24M
Revenue $646K, -5% YoY from $683K; gross margin improved to 89.5% from 88.4%.
-
NeurAxis reports over $8M in cumulative IB-Stim revenue through March 31, 2023
Over $8M in revenue from IB-Stim since commercial launch after FDA clearance for pediatric functional abdominal pain and IBS.
-
Neuraxis prices IPO of 1,098,667 shares at $6.00, raising ~$6.6M gross
Pricing of 1,098,667 shares at $6.00 per share; gross proceeds expected ~$6,592,000.
Executive changes
Departed
Dan Clarence
Chief Operating Officer
NRXS ·
Neuraxis, INC
On April 10, 2024, the employment of Dan Clarence, Chief Operating Officer of NeurAxis, Inc. (the "Company"), terminated effective immediately.
Appointed
Kristin Ferge
Director and Chairman of Audit Committee
NRXS ·
Neuraxis, INC
On March 7, 2024, the Board of Directors (the “Board”) of NeurAxis, Inc. (the “Company”) appointed Kristin Ferge to the Board to serve until the Company’s next annual meeting of shareholders.
Appointed
Timothy R. Henrichs
Chief Financial Officer
NRXS ·
Neuraxis, INC
On January 26, 2024, the Board appointed Mr. Henrichs to serve as the CFO (the “CFO Appointment”). Mr. Henrichs’s employment will begin on February 5, 2024
Departed
John Seale
Chief Financial Officer
NRXS ·
Neuraxis, INC
on January 30, 2024, John Seale resigned as the Company’s Chief Financial Officer (the “CFO”) effective as of the close of business on January 30th.
Departed
Timothy R. Henrichs
Director
NRXS ·
Neuraxis, INC
on January 25, 2024, Timothy R. Henrichs resigned as a member of the Board of Directors (the “Board”) of NeurAxis, Inc. (the “Company”), effective February 2, 2024.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.60 · Most common event other_material